Calendar of Events
Tuesday, July 25
Source: crossville-chronicle.com
📰 Bleeding Disorders News
Page 3 - Bleeding Disorders News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bleeding Disorders. Real-time updates on events, politics, business and more.
Lynn Malec, MD: FVIII Therapy Improves Levels in Pediatric Patients with Hemophilia A
Efaconescotog alfa defined a new therapy class by the US Food and Drug Administration (FDA) as the first and best-in-class high-sustained FVIII therapy.
Lynn Malec Drug Administration Versiti Blood Research Institute College Of Wisconsin Comprehensive Center Bleeding Disorders
Source: hcplive.com
Lynn Malec, MD: Efanesoctocog alfa Reduces Bleeds, Treatment Burden for Hemophilia
Efanesoctocog alfa demonstrates promising results in new phase 3 data emphasizing the drug's potential to address unmet needs within the hemophilia community.
Lynn Malec College Of Wisconsin Drug Administration Versiti Blood Research Institute International Society On Thrombosis International Society
Source: hcplive.com
Once-weekly Altuviiio offers bleed protection for children with severe hemophilia A
Once-weekly prophylaxis with a high-sustained factor VIII replacement therapy exhibited effective bleed protection for children with severe hemophilia A, according to the agent’s manufacturer.Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein (Altuviiio, Sanofi) is approved in the United States for routine prophylaxis and on-demand treatment to control bleeding episodes for
United States Lynn Malec Haemostasis Congress International Society On Thrombosis College Of Wisconsin Versiti Blood Research Institute
Source: healio.com
Press Release: ALTUVIIIO late-breaking data at ISTH
  ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing ...
Source: globenewswire.com
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing XTEND-Kids data confirm the efficacy and safety profile of ALTUVIIIO with simple, weekly 50...
Source: marketscreener.com